. . "Klasifikace karcinomu \u017Ealudku pomoc\u00ED panelu molekul\u00E1rn\u00EDch marker\u016F na b\u00E1zi amplifikace specifick\u00FDch gen\u016F" . "HER2, MYC, p16 a b-CAT, MLPA"@en . "Gastric cancer is the third most common malignant disease of the gastrointestinal tract in Czech Republic. In most cases the disease is diagnosed in an advanced stage and subsequent therapeutic options are then limited. This is especially true for the diffuse type of tumor. The aim, therefore, is to find suitable diagnostic, predictive and prognostic tools. An example is the molecular-genetic analysis of CDH1 gene in hereditary diffuse gastric cancer as a predictor of increased risk of second malignancies and risk of lobular breast cancer in women or MDM2 gene amplification and more. However, it is clear that for accurate estimation of prognosis and therapies not only diffuse type is necessary to find. The aim of this project is to compile a panel of molecular genetic markers of gene amplification fulfilling the role of diagnostic, predictive or prognostic factor in gastric cancer."@en . "Klasifikace karcinomu \u017Ealudku pomoc\u00ED panelu molekul\u00E1rn\u00EDch marker\u016F na b\u00E1zi amplifikace specifick\u00FDch gen\u016F"@cs . . "Karcinom \u017Ealudku p\u0159edstavuje t\u0159et\u00ED nej\u010Dast\u011Bj\u0161\u00ED malign\u00ED onemocn\u011Bn\u00ED tr\u00E1vic\u00EDho traktu v \u010CR. Ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F je onemocn\u011Bn\u00ED diagnostikov\u00E1no v pokro\u010Dil\u00E9m st\u00E1diu a n\u00E1sledn\u00E9 terapeutick\u00E9 mo\u017Enosti jsou pak omezeny. To plat\u00ED p\u0159edev\u0161\u00EDm pro difuzn\u00ED typ n\u00E1doru. Snahou tedy je, naj\u00EDt vhodn\u00E9 diagnostick\u00E9, prediktivn\u00ED a prognostick\u00E9 n\u00E1stroje. Takov\u00FDm p\u0159\u00EDkladem m\u016F\u017Ee b\u00FDt molekul\u00E1rn\u011B-genetick\u00E9 vy\u0161et\u0159en\u00ED genu CDH1 u heredit\u00E1rn\u00EDho difuzn\u00EDho karcinomu \u017Ealudku, jako prediktoru zv\u00FD\u0161en\u00E9ho rizika dal\u0161\u00EDch malignit a rizika lobul\u00E1rn\u00EDho karcinomu prsu u \u017Een nebo amplifikace genu MDM2 a dal\u0161\u00ED. Je v\u0161ak z\u0159ejm\u00E9, \u017Ee pro p\u0159esn\u011Bj\u0161\u00ED odhad progn\u00F3zy a l\u00E9\u010Debn\u00E9 terapie nejen u difuzn\u00EDch typ\u016F je nutn\u00E9 naj\u00EDt dal\u0161\u00ED molekul\u00E1rn\u00ED markery. C\u00EDlem tohoto projektu je sestavit panel molekul\u00E1rn\u011B-genetick\u00FDch marker\u016F na b\u00E1zi genov\u00E9 amplifikace spl\u0148uj\u00EDc\u00ED \u00FAlohu diagnostick\u00E9ho, prediktivn\u00EDho a nebo prognostick\u00E9ho faktoru u karcinomu \u017Ealudku." . . "8"^^ . "P(NT13640)" . "Classification of gastric cancer using molecular markers based on amplification of specific genes"@en . . . "Klasifikace karcinomu \u017Ealudku pomoc\u00ED panelu molekul\u00E1rn\u00EDch marker\u016F na b\u00E1zi amplifikace specifick\u00FDch gen\u016F"@cs . "978-80-904596-9-4" . "Kope\u010Dkov\u00E1, Marta" . . "Bene\u0161ov\u00E1, Lucie" . "4"^^ . "Classification of gastric cancer using molecular markers based on amplification of specific genes"@en . "[A466D99A07ED]" . "BOD, Brno" . . "http://www.registracni-system.cz/akce-brnenske-onkologicke-dny-2013/sjezd.php?p=read_abstrakt_program&idabstrakta=233" . "RIV/26475821:_____/13:#0000160" . . "Klasifikace karcinomu \u017Ealudku pomoc\u00ED panelu molekul\u00E1rn\u00EDch marker\u016F na b\u00E1zi amplifikace specifick\u00FDch gen\u016F" . "RIV/26475821:_____/13:#0000160!RIV13-MZ0-26475821" . "Min\u00E1rik, Marek" . . . "82696" . . . . . . . "Bel\u0161\u00E1nov\u00E1, Barbora" . . . "Karcinom \u017Ealudku p\u0159edstavuje t\u0159et\u00ED nej\u010Dast\u011Bj\u0161\u00ED malign\u00ED onemocn\u011Bn\u00ED tr\u00E1vic\u00EDho traktu v \u010CR. Ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F je onemocn\u011Bn\u00ED diagnostikov\u00E1no v pokro\u010Dil\u00E9m st\u00E1diu a n\u00E1sledn\u00E9 terapeutick\u00E9 mo\u017Enosti jsou pak omezeny. To plat\u00ED p\u0159edev\u0161\u00EDm pro difuzn\u00ED typ n\u00E1doru. Snahou tedy je, naj\u00EDt vhodn\u00E9 diagnostick\u00E9, prediktivn\u00ED a prognostick\u00E9 n\u00E1stroje. Takov\u00FDm p\u0159\u00EDkladem m\u016F\u017Ee b\u00FDt molekul\u00E1rn\u011B-genetick\u00E9 vy\u0161et\u0159en\u00ED genu CDH1 u heredit\u00E1rn\u00EDho difuzn\u00EDho karcinomu \u017Ealudku, jako prediktoru zv\u00FD\u0161en\u00E9ho rizika dal\u0161\u00EDch malignit a rizika lobul\u00E1rn\u00EDho karcinomu prsu u \u017Een nebo amplifikace genu MDM2 a dal\u0161\u00ED. Je v\u0161ak z\u0159ejm\u00E9, \u017Ee pro p\u0159esn\u011Bj\u0161\u00ED odhad progn\u00F3zy a l\u00E9\u010Debn\u00E9 terapie nejen u difuzn\u00EDch typ\u016F je nutn\u00E9 naj\u00EDt dal\u0161\u00ED molekul\u00E1rn\u00ED markery. C\u00EDlem tohoto projektu je sestavit panel molekul\u00E1rn\u011B-genetick\u00FDch marker\u016F na b\u00E1zi genov\u00E9 amplifikace spl\u0148uj\u00EDc\u00ED \u00FAlohu diagnostick\u00E9ho, prediktivn\u00EDho a nebo prognostick\u00E9ho faktoru u karcinomu \u017Ealudku."@cs . . .